Skip to main
CMPS
CMPS logo

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 15 analyst ratings
Strong Buy
Strong Buy 67%
Buy 27%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways PLC is advancing its proprietary psilocybin therapy, COMP360, targeting treatment-resistant depression (TRD) with promising efficacy data indicating potential superiority over existing treatments like Spravato, which recently surpassed $1 billion in annual revenue. The company's innovative therapeutic approach, designed to address a large and underserved patient population, suggests significant commercial viability, particularly with projections for expanding into post-traumatic stress disorder (PTSD) as mental health initiatives for veterans gain government support. The favorable data regarding the durability of response from COMP360, with patients showing sustained benefits for up to 12 weeks, further reinforces the potential for a successful treatment model, positioning Compass Pathways for positive growth in the mental health market.

Bears say

Compass Pathways PLC faces significant risks regarding the FDA approval of its psilocybin therapy, COMP360, following a general trend of negative sentiment in the psychedelic sector, highlighted by Lykos Therapeutics' unfavorable AdComm and subsequent Complete Response Letter (CRL). The overarching concerns stem from the potential for COMP360 and similar pipeline programs to encounter clinical trial failures or safety issues, which could severely hamper the company's prospects. Additionally, a sustained response rate of only ~20% in related studies raises questions about the efficacy of its treatment approach, further contributing to a cautious outlook on the company's stock performance.

COMPASS Pathways (CMPS) has been analyzed by 15 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 27% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Strong Buy based on their latest research and market trends.

According to 15 analysts, COMPASS Pathways (CMPS) has a Strong Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.